Faculty

Back to Index
Vito Michele Campese, MD
Professor of Medicine
Medicine
IRD 804 Off Campus Los Angeles
+1 323 226 7337

Overview

A native of Bari, Italy, Dr. Campese graduated medical school summa cum laude before coming to the Keck School of Medicine on a fellowship in 1974. Since his time at USC, Dr. Campese has established himself as one on the most prominent nephrologists in the field and currently heads Keck’s division of Nephrology.

In addition to his numerous academic and administrative appointments, Dr. Campese is a former president of the Italian-American Society of Nephrologists and is currently a member of the Program Committee on the Council on High Blood Pressure Research for the American Heart Association.

Awards

The Domenico Cotugno Medal and Award in Nephrology

The Regione Puglia Targa d'Oro Award for Contribution to Science

Rotary Club International: Rotary Club Contribution to Science Award, 2002

University Kidney Disease Research Disease

The Italians Society of Nephrology : Honorary Membership, 2007

Publications

Campese VM. Predictors of blood pressure response to spironolactone. J Hypertens. 2016 May; 34(5):845-7. View in: PubMed

Campese VM. The Mesoamerican nephropathy: a regional epidemic of chronic kidney disease? Nephrol Dial Transplant. 2016 Mar; 31(3):335-6. View in: PubMed

Campese VM. Statins and the kidney: friend or foe? Lancet Diabetes Endocrinol. 2015 Mar; 3(3):161-2. View in: PubMed

Campese VM, Lakdawala R. The Challenges of Blood Pressure Control in Dialysis Patients. Recent Pat Cardiovasc Drug Discov. 2015; 10(1):34-59. View in: PubMed

Campese VM. Left ventricular function and chronic kidney disease: how soon does it start? Nephrol Dial Transplant. 2014 Nov; 29(11):1989-91. View in: PubMed

Amarenco P, Callahan A, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KM, Wilson DJ, Zivin JA. Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial. Stroke. 2014 Oct; 45(10):2974-82. View in: PubMed

Campese VM. Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clin Exp Nephrol. 2014 Apr; 18(2):291-5. View in: PubMed

Campese VM. Reply to 'Resistant hypertension and central aortic pressure'. J Hypertens. 2014 Mar; 32(3):699. View in: PubMed

Campese VM. Pathophysiology of resistant hypertension in chronic kidney disease. Semin Nephrol. 2014; 34(5):571-6. View in: PubMed

Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Böhm M, Campese VM, Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013 Dec 3; 62(22):2031-45. View in: PubMed

Campese VM. Interventional hypertension: a new hope or a new hype? The need to redefine resistant hypertension. J Hypertens. 2013 Nov; 31(11):2118-21; discussion 2122. View in: PubMed

Ku E, Campese V. Is lipid management effective for all stages of CKD? . Blood Purif. 2013; 35(1-3):26-30. View in: PubMed

Koya D, Campese VM. Statin use in patients with diabetes and kidney disease: the Japanese experience. J Atheroscler Thromb. 2013; 20(5):407-24. View in: PubMed

Park J, Middlekauff HR, Campese VM. Abnormal sympathetic reactivity to the cold pressor test in overweight humans. Am J Hypertens. 2012 Dec; 25(12):1236-41. View in: PubMed

Park J, Campese VM. Resistant hypertension and obstructive sleep apnea in end-stage renal disease. J Hypertens. 2012 May; 30(5):880-1. View in: PubMed

Ku E, Ananthapanyasut W, Campese VM. IgA nephropathy in a patient with ulcerative colitis, Graves' disease and positive myeloperoxidase ANCA. Clin Nephrol. 2012 Feb; 77(2):146-50. View in: PubMed

Campese VM, Ku E, Bigazzi R, Bianchi S. Do HMG-CoA reductase inhibitors improve kidney function? The saga continues. J Nephrol. 2011 Sep-Oct; 24(5):550-3. View in: PubMed

Campese VM, Ku E, Park J. Sympathetic renal innervation and resistant hypertension. Int J Hypertens. 2011; 2011:814354. View in: PubMed

Gill IS, Eisenberg MS, Aron M, Berger A, Ukimura O, Patil MB, Campese V, Thangathurai D, Desai MM. "Zero ischemia" partial nephrectomy: novel laparoscopic and robotic technique. Eur Urol. 2011 Jan; 59(1):128-34. View in: PubMed

Lu Y, Ku E, Campese VM. Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Curr Hypertens Rep. 2010 Aug; 12(4):303-6. View in: PubMed

Campese V, Schneider EL. Reevaluating the use of antihypertensive medications, a first step toward reducing polypharmacy in very old patients. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):621-4. View in: PubMed

Schneider EL, Campese VM. Adverse drug responses: An increasing threat to the well-being of older patients: Comment on "Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older". Arch Intern Med. 2010 Jul 12; 170(13):1148-9. View in: PubMed

Campese VM. Oxidative stress and sympathetic activity in hypertension. Am J Hypertens. 2010 May; 23(5):456. View in: PubMed

Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis. 2010 Apr; 55(4):671-81. View in: PubMed

Cioni A, Sordini C, Cavallini I, Bigazzi R, Campese VM. Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients. Perit Dial Int. 2010 Jan-Feb; 30(1):66-71. View in: PubMed

Ku E, Campese VM. Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. Pediatr Nephrol. 2009 Dec; 24(12):2301-7. View in: PubMed

Ku E, Campese VM. Aldosterone and hypertension in African Americans. Am J Hypertens. 2009 Dec; 22(12):1234. View in: PubMed

Ku E, Park J, Vidhun J, Campese V. The hazards of dual renin-angiotensin blockade in chronic kidney disease. Arch Intern Med. 2009 Jun 8; 169(11):1015-8. View in: PubMed

Ku E, Nobakht N, Campese VM. Lixivaptan: a novel vasopressin receptor antagonist. Expert Opin Investig Drugs. 2009 May; 18(5):657-62. View in: PubMed

Bai Y, Jabbari B, Ye S, Campese VM, Vaziri ND. Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension. Am J Nephrol. 2009; 29(5):483-92. View in: PubMed

Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol. 2008 Dec; 105(6):1873-6. View in: PubMed

Park J, Campese VM, Middlekauff HR. Exercise pressor reflex in humans with end-stage renal disease. Am J Physiol Regul Integr Comp Physiol. 2008 Oct; 295(4):R1188-94. View in: PubMed

Bigazzi R, Bianchi S, Buoncristiani E, Campese VM. Increased cardiovascular events in hypertensive patients with insulin resistance: a 13-year follow-up. Nutr Metab Cardiovasc Dis. 2008 May; 18(4):314-9. View in: PubMed

Campese VM, Park J. HMG-CoA reductase inhibitors and renal function. Clin J Am Soc Nephrol. 2007 Nov; 2(6):1100-3. View in: PubMed

Campese VM. Diuretics are preferred over angiotensin II-converting enzyme inhibitors for initial therapy of uncomplicated hypertension. Am J Kidney Dis. 2007 Aug; 50(2):197-202. View in: PubMed

Campese VM, Ye S. A vitamin-E-fortified diet reduces oxidative stress, sympathetic nerve activity, and hypertension in the phenol-renal injury model in rats. J Am Soc Hypertens. 2007 Jul-Aug; 1(4):242-50. View in: PubMed

Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int. 2007 Jun; 71(12):1215-22. View in: PubMed

Campese VM, Sindhu RK, Ye S, Bai Y, Vaziri ND, Jabbari B. Regional expression of NO synthase, NAD(P)H oxidase and superoxide dismutase in the rat brain. Brain Res. 2007 Feb 23; 1134(1):27-32. View in: PubMed

Park J, Campese V. Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Greenwich). 2007 Jan; 9(1 Suppl 1):7-12. View in: PubMed

Campese VM, Park J. Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks. J Hypertens. 2006 Nov; 24(11):2157-9. View in: PubMed

Campese VM, Park J. The kidney and hypertension: over 70 years of research. J Nephrol. 2006 Nov-Dec; 19(6):691-8. View in: PubMed

Ye S, Zhong H, Yanamadala S, Campese VM. Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension. 2006 Aug; 48(2):309-15. View in: PubMed

Bigazzi R, Bianchi S, Batini V, Guzzo D, Campese VM. Metabolic risk factors and markers of cardiovascular and renal damage in overweight subjects. Am J Hypertens. 2006 Apr; 19(4):426-31. View in: PubMed

Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int. 2006 Mar; 69(6):967-73. View in: PubMed

Campese VM, Hadaya B, Chiu J. HMG-CoA reductase inhibitors and the kidney. Curr Hypertens Rep. 2005 Oct; 7(5):337-42. View in: PubMed

Sica DA, Giles TD, Black HR, Campese VM. ACE inhibitors: over two decades of use. J Clin Hypertens (Greenwich). 2005 Sep; 7(9):531-7. View in: PubMed

Campese VM, Shaohua Y, Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension. 2005 Sep; 46(3):533-9. View in: PubMed

Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005 Jul; 46(1):45-51. View in: PubMed

Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. 2005 Mar; 16 Suppl 1:S11-7. View in: PubMed

Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis. 2005 Jan; 45(1):2-14. View in: PubMed

Nadim MK, Dua R, Campese VM. Antihypertensive drugs and the kidney. Curr Cardiol Rep. 2004 Nov; 6(6):403-8. View in: PubMed

Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol. 2004 Aug; 287(2):H695-703. View in: PubMed

Davidson MB, Bazargan M, Bakris G, Peters Harmel A, Campese V, Basta E. ImmunoDip: an improved screening method for microalbuminuria. Am J Nephrol. 2004 May-Jun; 24(3):284-8. View in: PubMed

Epstein M, Campese VM. Evolving role of calcium antagonists in the management of hypertension. Med Clin North Am. 2004 Jan; 88(1):149-65. View in: PubMed

Campese VM. A new model of neurogenic hypertension caused by renal injury: pathophysiology and therapeutic implications. Clin Exp Nephrol. 2003 Sep; 7(3):167-71. View in: PubMed

Yang LE, Zhong H, Leong PK, Perianayagam A, Campese VM, McDonough AA. Chronic renal injury-induced hypertension alters renal NHE3 distribution and abundance. Am J Physiol Renal Physiol. 2003 May; 284(5):F1056-65. View in: PubMed

Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003 Mar; 41(3):565-70. View in: PubMed

Yang LE, Leong PK, Ye S, Campese VM, McDonough AA. Responses of proximal tubule sodium transporters to acute injury-induced hypertension. Am J Physiol Renal Physiol. 2003 Feb; 284(2):F313-22. View in: PubMed

Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002 Aug; 15(8):717-24. View in: PubMed

Campese VM, Mozayeni P, Ye S, Gumbard M. High salt intake inhibits nitric oxide synthase expression and aggravates hypertension in rats with chronic renal failure. J Nephrol. 2002 Jul-Aug; 15(4):407-13. View in: PubMed

Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep. 2002 Jun; 4(3):256-60. View in: PubMed

Ye S, Zhong H, Duong VN, Campese VM. Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension. 2002 Jun; 39(6):1101-6. View in: PubMed

Ferrario CM, Smith RD, Brosnihan B, Chappell MC, Campese VM, Vesterqvist O, Liao WC, Ruddy MC, Grim CE. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens. 2002 Jun; 15(6):557-64. View in: PubMed

Campese VM, Ye S, Zhong H. Downregulation of neuronal nitric oxide synthase and interleukin-1beta mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension. 2002 Feb; 39(2 Pt 2):519-24. View in: PubMed

Powered bySC CTSI